Bristol Myers Squibb (CELG-RI) Profit After Tax (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Profit After Tax for 18 consecutive years, with $3.4 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Profit After Tax rose 158.64% year-over-year to $3.4 billion; the TTM figure through Jun 2026 stood at $9.4 billion (up 85.92% YoY), while the FY2025 annual figure was $7.1 billion, up 178.84% from the prior year.
• Profit After Tax rose to $3.4 billion in Q2 2026 per CELG-RI's latest filing, from $2.7 billion in the prior quarter.
• Across five years, Profit After Tax topped out at $3.4 billion in Q2 2026 and bottomed at -$11.9 billion in Q1 2024.
• Historically, Profit After Tax has averaged $1.0 billion across 5 years, with a median of $1.7 billion in 2022.
• Annual changes were most pronounced in 2024 — Profit After Tax sank 626.57% — and 2025, when it surged 1406.94%.
• Bristol Myers Squibb's Profit After Tax stood at $1.6 billion in 2022, then gained by 9.24% to $1.8 billion in 2023, then slumped by 95.91% to $72.0 million in 2024, then soared by 1406.94% to $1.1 billion in 2025, then surged by 213.0% to $3.4 billion in 2026.
• Business Quant data shows CELG-RI's Profit After Tax at $3.4 billion in Q2 2026, $2.7 billion in Q1 2026, and $1.1 billion in Q4 2025.